Establishing the role of tigecycline in an era of antimicrobial resistance

References

• Meagher AK, Ambrose PG, Grasela TH, Eillis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis.41, S333–S340 (2005).
   PubMed Web of Science ®Google Scholar
• Wyeth. Tygacil (tigecycline) package insert (2005).
   Google Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis.41, S303–S314 (2005).
   PubMed Web of Science ®Google Scholar
• Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J. Antimicrob. Chemother.53, 592–599 (2004).
   PubMed Web of Science ®Google Scholar
• Bergeron J, Ammirati M, Danley D et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother.40, 2226–2228 (1996).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Homenuik K, Nichol K. The glycylcyclines: a comparative review with the tetracyclines. Drugs64, 63–88 (2004).
   PubMed Web of Science ®Google Scholar
• Van Wart SA, Cirincione BB, Ludwig EA et al. Population pharmacokinetics of tigecycline in healthy volunteers. J. Clin. Pharm.47, 727–737 (2007).
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother.49, 220–229 (2005).
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M et al. Serum, rissue, and body fluid concentrations of tigecycline after a single 100mg dose. J. Antimicrob. Chemother.58, 1221–1229 (2006).
   PubMed Web of Science ®Google Scholar
• van Ogtrop ML, Andes D, Stamstad TJ et al.In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram positive and Gram negative bacteria. Antimicrob. Agents Chemother.44, 943–949 (2000).
   PubMed Web of Science ®Google Scholar
• Conte JE, Golden JA, Kelly MG, Zurlinden E. Steady state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents25, 523–529 (2005).
   PubMed Web of Science ®Google Scholar
• Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightengale CH. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother.49, 1629–1632 (2005).
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis.52, 203–208 (2005).
   PubMed Web of Science ®Google Scholar
• Goff D, Dowzicky M. Prevalence and regional variation in methicillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J. Med. Microbiol.56, 1189–1195 (2007).
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis.52, 181–186 (2005).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn. Microbiol. Infect. Dis.60, 433–436 (2008).
   PubMed Web of Science ®Google Scholar
• Bouchillon S K, Hoban DJ, Johnson BM et al.In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the USA Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn. Microbiol. Infect. Dis.52, 173–179 (2005).
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader SH, Stilwell MG et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis.52, 187–193 (2005).
   PubMed Web of Science ®Google Scholar
• Betriu C, Culebras E, Gomez M, Rodriguez-Avial I, Picazo JJ. In vitro activity of tigecycline against Bacteroides species. J. Antimicrob. Chemother.56, 349–352 (2005).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Fritsche TR, Sader HS, Jones RN. Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates. Clin. Infect. Dis.46, 1324–1326 (2008).
   PubMed Web of Science ®Google Scholar
• Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob. Agents Chemother.48, 4479–4481 (2004).
   PubMed Web of Science ®Google Scholar
• Conejo MC, Hernandez JR, Pascual A. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended spectrum B-lactamases or plasmid-mediated AmpC-type B-lactamases. Diagn. Microbiol. Infect. Dis. (2008) (In Press).
   Google Scholar
• Castahheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad spectrum antimicrobials tested against serine carbapenemase- and metallo-β-lactamase-producing Enterobacteriaceae: report from the sentry antimicrobial surveillance program. Antimicrob Agents Chemother.52, 570–573 (2008).
   PubMedGoogle Scholar
• Peterson PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram positive pathogens. Antimicrob. Agents Chemother.46, 2595–2601 (2002).
   PubMedGoogle Scholar
• Denys GA, Koch KM, Dowzicky MJ. Distribution of resistant Gram-positive organisms across the census regions of the USA and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Am. J. Infect. Control35, 521–526 (2006).
   Google Scholar
• Scheetz MH, Qi C, Warren JR et al.In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.51, 1621–1626 (2007).
   PubMed Web of Science ®Google Scholar
• Mezzatesta ML, Truvato G, Gona F et al.In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann. Clin. Microbiol. Antimicrob.7, 1–7 (2008).
   PubMedGoogle Scholar
• Woodford N, Hill RLR, Livermore DM. In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J. Antimicrob. Chemother.59, 582–583 (2007).
   PubMed Web of Science ®Google Scholar
• Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J. Antimicrob. Chemother.59, 583–584 (2007).
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the USA and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn. Microbiol. Infect. Dis.57, 423–428 (2007).
   PubMed Web of Science ®Google Scholar
• Curcio D, Fernandez F. Acinetobacterspp. susceptibility to tigecycline: a worldwide perspective. J. Antimicrob. Chemother.60, 449–450 (2007).
   PubMedGoogle Scholar
• Laplante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Microbiol. Infect. Dis.50, 125–130 (2004).
   PubMed Web of Science ®Google Scholar
• Souli M, Kontopidou F V, Koratzanis E et al.In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother.50, 3166–3169 (2006).
   PubMed Web of Science ®Google Scholar
• Pliatsika V, Afkou Z, Protonotariou E, Sofianou D. In vitro activity of tigecycline against metallo-B-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother.60, 1406–1407 (2007).
   PubMedGoogle Scholar
• Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PA01. Antimicrob. Agents Chemother.47, 972–978 (2003).
   PubMed Web of Science ®Google Scholar
• Visalli MA, Murphy E, Projan SJ et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother.47, 665–669 (2003).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R et al.Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother.59, 128–131 (2007).
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Goff DA, Stevenson KB, Mangino JM. Early experience with tigecycline for the management of multi-drug resistant Acinetobacter baumannii ventilator associated pneumonia and/or bacteremia. Pharmacotherapy27, 980–987 (2007).
   PubMed Web of Science ®Google Scholar
• Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy27, 1198–1201 (2007).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Adams JA, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob. Agents Chemother.51, 2065–2069 (2007).
   PubMed Web of Science ®Google Scholar
• Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob. Agents Chemother.48, 3298–3304 (2004).
   PubMed Web of Science ®Google Scholar
• Magnet S, Courvalin P, Lambert T. Resistance–nodulation–cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob. Agents Chemother.45, 3375–3380 (2001).
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Fruncillo RJ, Micalizzi M et al. Effects of age and sex on single dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob. Agents Chemother.49, 1656–1659 (2005).
   PubMed Web of Science ®Google Scholar
• Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin. Ther.26, 704–714 (2004).
   PubMed Web of Science ®Google Scholar
• Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a Phase 2 clinical trial. In: Program and Abstracts of the 43rd Conference of Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003. American Society of Microbiology, Abstract L-739, 416 (2003).
   Google Scholar
• Babinchak T, Ellis-Grosse EJ, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections. Analysis of pooled clinical data. Clin. Infect. Dis.41, S354–S367 (2005).
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin–aztreonam. Clin. Infect. Dis.41, S341–S353 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 Phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis.61, 329–338 (2008).
   PubMed Web of Science ®Google Scholar
• Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis.46, 567–570 (2008).
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg. Infect. Dis.14, 512–513 (2008).
   PubMed Web of Science ®Google Scholar
• Evagelopoulou P, Myrianthefs P, Markogiannakis A, Baltopoulos G, Tsakris A. Multidrug-resistant Klebsiella pneumoniae mediastinitis safely and effectively treated with prolonged administration of tigecycline. Clin. Infect. Dis.46, 1932–1933 (2008).
   PubMed Web of Science ®Google Scholar
• Wadi JA, Al Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann. Saudi Med.27, 456–458 (2007).
   PubMed Web of Science ®Google Scholar
• Taccone FS, Rodriguez-Villalobos H, De Backer D et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur. J. Clin. Microbiol. Infect. Dis.25, 257–260 (2006).
   PubMed Web of Science ®Google Scholar
• Khanna N, Inkster T. Methicillin-resistant Staphylococcus aureus hepatic abscess treated with tigecycline. J. Clin. Pathol.61, 967–968 (2008).
   PubMedGoogle Scholar
• Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother.58, 1062–1065 (2006).
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP et al.In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983–2004. Antimicrob. Agents Chemother.51, 2716–2719 (2007).
   PubMed Web of Science ®Google Scholar
• Raible DG, Zimmerman JJ, Harper DM, Speth JL. Pharmacokinetics and pharmacodynamics of tigecycline and warfarin co-administered to healthy men. In: Program and Abstracts of the 44th Conference of Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October–2 November 2004.
   Google Scholar
• Zimmerman JJ, Harper DM, Speth JL, Raible DG, Fruncillo, RJ. Tigecycline and digoxin co-administered to healthy men. In: Program and Abstracts of the 44th Conference of Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30 October–2 November 2004. (Abstract A-460).
   Google Scholar